Replies to post #103879 on Biotech Values

[DewDiligence]

Court rules APP Pharma lacks standing to appeal ruling in the Angiomax patent suit between MDCO and the USPTO, which was decided in MDCO’s favor:

http://finance.yahoo.com/news/The-Medicines-Company-iw-678514381.html?x=0&.v=1

Touch luck for APP Phrama, which had hoped to launch a generic version of Angiomax and will now have to wait until the expiration of the extended patent.

(Note: APP Pharma has nothing to do with APPA.)